Tatva Chintan Pharma Chem Limited share price

Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, consumer electronics, pharmaceutical, agrochemicals, paints and coatings, dyes, and personal care sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.Read more

Website NSE हिंदी में BSE

Basic MaterialsSpecialty ChemicalsNSE: TATVAISIN INE0GK401011

16 Oct 2026, 3:29 PM IST₹1,944.00▲ 3.30 (0.17%)

Market Cap₹ 4,547 Cr.
Current Price₹ 1,944.00
High / Low₹ 2,009 / 1,044
Stock P/E88.5
Book Value₹ 334
Dividend Yield0.10 %
ROCE7.5 %
ROE5.50 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 21.97
Price / Book5.82
OPM11.9 %
Debt / Equity0.15
Sales growth (3Y)6.1 %
Profit growth (3Y)-2.6 %
Promoter holding74.2 %
EV / EBITDA42.7
Beta0.30
All-time high₹ 2,978

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
TATVA	+18.05%	+37.08%	+51.41%	+45.71%	+51.15%	+7.73%	-3.06%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Tatva Chintan Pharma Chem Limited is in the Specialty Chemicals industry (Basic Materials), with a market value of ₹4,547 crore.
It trades at 88.5 times its last 12 months' earnings and 5.8 times book value.
Revenue grew 6.1% a year over the last 3 years, profit -2.6% a year.
Return on equity was 5.5% and return on capital employed 7.5% in the latest year.
Debt was 0.15 times shareholders' equity.
The share price is 3.2% below its 52-week high and up 51.2% over one year.
Promoters and insiders hold about 74.2%; institutions about 5.9%.

Pros

Latest quarter (Jun 2026): sales up 43% and profit up 140% from a year ago.
Borrowings are moderate at 0.15 times shareholders' equity.
Promoters hold a large stake of 72.02%.

Cons

Return on equity has been low: 3.7% on average over the last 3 years.
Profit growth has been weak: -2.6% a year over the last 3 years.
Institutional (FII + DII) holding has fallen by 9.7 points over 3 years.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Tatva Chintan Pharma Chem Limited

Employees: 793
Head office: Vadodara

Basic MaterialsSpecialty Chemicals

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Tatva Chintan Pharma Chem	1,944.00	88.5	4,547	0.10	16	140.28	167	42.95	7.5	5.5	5.82	11.9	0.15	74.16	506	6.1
2.	Asian Paints	2,331.90	46.9	2,23,546	1.17	1,539	39.96	10,521	17.89	24.4	21.2	10.47	15.8	0.18	52.90	35,541	1.1
3.	Solar Industries India	20,011.00	90.9	1,81,080	0.06	653	92.66	3,668	70.26	29.5	31.4	28.85	24.9	0.29	43.92	9,612	12.4
4.	Pidilite Industries	1,502.80	57.8	1,53,066	0.76	884	30.29	4,552	21.27	28.5	23.8	14.12	21.6	0.04	69.28	14,601	7.4
5.	Berger Paints India	473.95	45.4	55,263	0.85	404	54.30	3,584	32.53	20.6	17.2	7.99	12.6	0.09	75.60	11,790	4.2
6.	Linde India	6,184.50	96.5	52,744	0.07	105	-11.67	694	17.32	16.3	13.6	12.36	26.7	0.02	77.98	2,530	0.3
7.	Gujarat Fluorochemicals	4,402.90	79.1	48,366	0.07	219	19.02	1,588	23.97	9.6	7.6	6.32	17.1	0.29	66.44	4,875	-4.5
8.	Himadri Speciality Chemical	660.70	41.5	33,337	0.12	230	47.53	1,432	26.20	21.0	17.8	7.08	20.1	0.16	57.43	4,658	3.7
9.	Acutaas Chemicals	3,206.00	68.2	26,248	0.08	74	18.85	330	9.32	27.7	24.0	15.88	33.5	0.02	38.31	1,329	29.4
10.	Aether Industries	1,538.60	86.6	20,422	0.00	63	33.45	327	27.49	12.1	9.4	8.31	24.0	0.19	76.58	1,160	20.2
	Median: 36 Co.	2,137.95	41.6	9,249	0.27	224	36.70	1,510	25.08	20.8	11.6	5.61	12.8	0.16	67.86	4,767	5.5

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	114	97	84	98	105	83	86	108	117	124	131	134	167
YOY Sales Growth %		7.30%	-30.18%	-21.08%	-7.78%	-13.63%	2.01%	9.77%	10.81%	47.94%	52.90%	24.36%	42.95%
	93	76	73	83	93	78	79	99	100	101	106	106	135
Material Cost %	51%	39%	44%	42%	54%	51%	48%	53%	50%	44%	42%	42%	45%
Employee Cost %	10%	15%	18%	15%	12%	15%	15%	13%	12%	12%	13%	13%	10%
Other Expenses %	20%	26%	25%	27%	22%	27%	28%	25%	23%	25%	26%	24%	26%
Operating Profit	21	20	11	16	13	6	7	9	17	22	25	28	32
OPM %	19%	21%	13%	16%	12%	7%	8%	8%	15%	18%	19%	21%	19%
	1	1	1	5	1	0	0	1	1	1	2	-0	3
Exceptional items													-1
Interest	3	3	0	0	0	0	0	0	0	1	0	1	2
Depreciation	6	7	7	6	7	7	7	7	9	9	9	10	11
Profit before tax	13	11	5	14	7	-1	-0	2	9	14	18	17	21
	29%	31%	34%	30%	23%			49%	27%	27%	14%	38%	24%
Current tax	2	2	1	2	1	-0	0	1	2	2	5	3	1
Deferred tax	1	2	1	2	1	-0	-0	0	1	1	-2	3	4
	10	8	3	10	5	-1	0	1	7	10	15	10	16
Profit to shareholders	10	8	3	10	5	-1	0	1	7	10	15	10	16
YOY Profit Growth %		9.41%	-70.27%	-43.29%	-45.19%	-108.53%	-96.01%	-89.29%	27.68%		10,889.13%	902.04%	140.28%
EPS in Rs	4.29	3.43	1.48	4.11	2.23	-0.29	0.06	0.44	2.84	4.24	6.49	4.41	6.83
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	106	93	86	94	94	81	84	108	109	116	139	133	147
YOY Sales Growth %		10.16%	-24.19%	-21.33%	-11.59%	-12.54%	-2.41%	14.60%	16.39%	43.11%	64.99%	23.24%	34.37%
	86	72	74	80	86	76	78	100	94	95	112	106	123
Material Cost %	50%	37%	46%	43%	55%	53%	51%	56%	50%	45%	46%	45%	45%
Employee Cost %	11%	15%	15%	15%	14%	16%	16%	13%	13%	13%	12%	13%	11%
Other Expenses %	20%	25%	24%	27%	23%	26%	27%	23%	23%	24%	22%	22%	27%
Operating Profit	20	21	12	14	8	5	6	8	15	21	27	27	24
OPM %	18%	22%	14%	15%	8%	6%	7%	7%	14%	18%	19%	20%	16%
	1	1	1	5	1	1	0	1	1	1	2	-0	4
Exceptional items													-1
Interest	3	3	0	0	0	0	0	0	0	1	0	1	2
Depreciation	6	7	7	6	7	7	7	7	9	9	9	10	11
Profit before tax	12	12	7	12	2	-2	-2	2	7	12	19	15	14
	30%	30%	29%	33%	29%			30%	27%	28%	15%	40%	26%
Current tax	2	2	1	2	0	-0	-0	-0	1	2	4	3
Deferred tax	1	2	1	2	0	-0	-0	0	1	1	-1	3	4
	8	8	5	8	2	-1	-1	1	5	9	16	9	10
YOY Profit Growth %		56.07%	-55.94%	-48.95%	-81.72%	-113.54%	-125.05%	-86.72%	240.38%			724.02%	103.51%
EPS in Rs	3.72	3.63	1.99	3.52	0.64	-0.47	-0.50	0.47	2.19	3.82	6.84	3.86	4.47
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	434	424	394	383	506	556
YOY Sales Growth %		-2.31%	-7.11%	-2.74%	32.18%
	325	363	325	349	413	448
Material Cost %	45%	53%	44%	52%	44%	43%
Employee Cost %	7%	9%	14%	14%	12%	12%
Other Expenses %	23%	23%	24%	25%	25%	25%
Operating Profit	108	61	68	34	93	108
OPM %	25%	14%	17%	9%	18%	19%
	9	6	8	2	4	5
Exceptional items		-4				-1
Interest	5	8	7	1	3	5
Depreciation	8	10	26	28	37	38
Profit before tax	104	45	44	8	57	69
	8%	-2%	30%	25%	26%	26%
Current tax	19	3	8	2	12
Deferred tax	-11	-4	6	0	3
	96	45	30	6	42	51
Profit to shareholders	96	45	30	6	42	51
YOY Profit Growth %		-52.56%	-33.27%	-81.18%	636.11%
EPS in Rs	44.59	20.52	13.26	2.44	17.98	21.97
Dividend Payout %		10%	15%	82%	6%

Compounded Sales Growth

3 Years:: 6%
TTM:: 41%

Compounded Profit Growth

3 Years:: -3%
TTM:: 618%

Stock Price CAGR

5 Years:: -3%
3 Years:: 8%
1 Year:: 51%

Return on Equity

4 Years:: 5%
Last Year:: 6%

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	428	403	379	366	496	534
YOY Sales Growth %		-5.79%	-6.05%	-3.24%	35.45%
	322	348	312	341	407	436
Material Cost %	46%	55%	44%	54%	47%	45%
Employee Cost %	7%	10%	14%	14%	13%	12%
Other Expenses %	22%	22%	24%	25%	23%	24%
Operating Profit	106	55	67	26	89	98
OPM %	25%	14%	18%	7%	18%	18%
	11	6	8	4	4	6
Exceptional items		-4				-1
Interest	5	8	7	1	3	5
Depreciation	8	10	26	28	37	38
Profit before tax	103	39	42	0	53	60
	7%	-4%	31%	29%	26%	26%
Current tax	18	2	7	0	10
Deferred tax	-11	-4	6	0	4
	96	40	29	0	39	44
YOY Profit Growth %		-57.84%	-27.47%	-98.89%	11,851.68%
EPS in Rs	44.65	18.26	12.82	0.14	16.71	18.99
Dividend Payout %		11%	16%	1,431%	6%

Compounded Sales Growth

3 Years:: 7%
TTM:: 40%

Compounded Profit Growth

3 Years:: -1%
TTM:: 1,023%

Stock Price CAGR

5 Years:: -3%
3 Years:: 8%
1 Year:: 51%

Return on Equity

4 Years:: 5%
Last Year:: 6%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	22	23	23	23
Reserves	493	714	715	758
	170	14	36	120
Long term borrowings	4	1		5
Short term borrowings	166	14	36	115
	74	67	61	102
Trade payables	32	45	33	58
Current liabilities	239	80	96	213
Total Liabilities	759	819	836	1,004
	427	499	547	627
Gross block	462	560	634	748
Accumulated depreciation	35	60	87	120
Goodwill & intangibles	0	4	6	7
CWIP	231	73	22	23
	102	246	268	353
Inventories	162	153	134	196
Trade receivables	84	70	90	119
Cash & equivalents	27	35	11	6
Current assets	312	298	265	350
Total Assets	759	819	836	1,004

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	28	98	25	31
Profit for the year	45	30	6	42
Working capital changes	-24	34	-8	-62
Direct taxes paid	-9	-9	-4	-8
	-101	-121	-65	-116
Fixed assets purchased	-203	-129	-76	-114
Fixed assets sold	0	0	0	0
Investments purchased		-21		-9
Investments sold	97	25	10	4
	38	31	17	79
Proceeds from borrowings	1		26	85
Repayment of borrowings	-14	-9	-3	-1
Interest paid	-8	-7	-1	-3
Dividends paid	-4	-5	-5	-2
Net Cash Flow	-36	8	-24	-5
Free Cash Flow	-175	-30	-51	-82

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	8.8%	4.8%	0.8%	5.5%
ROCE	10.1%	6.7%	1.1%	7.5%
Operating margin	14.0%	11.3%	1.8%	11.9%
Net margin	10.8%	7.8%	1.5%	8.4%
Debt / equity	0.33	0.02	0.05	0.15
Current ratio	1.31	3.74	2.76	1.64
Debtor days	73	65	86	87
Inventory days	253	305	235	302
Days payable	50	90	57	90
Cash conversion cycle	276	280	264	299
Working capital days	64	204	163	99

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 72.02%
FIIs 4.38%
DIIs 3.21%
Public 20.39%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	72.02%	72.02%	72.02%	72.02%	72.02%	72.02%	72.02%	72.02%	72.02%	72.02%	72.02%	72.02%
	4.21%	3.65%	3.37%	3.33%	3.36%	3.30%	3.26%	3.39%	4.17%	3.82%	3.93%	4.38%
Foreign portfolio investors (Cat. I)	4.16%	3.57%	3.37%	3.33%	3.36%	3.28%	3.23%	3.37%	3.79%	3.67%	3.84%	3.92%
Foreign portfolio investors (Cat. II)	0.05%	0.08%				0.02%	0.03%	0.03%	0.38%	0.14%	0.09%	0.46%
	13.06%	12.84%	10.63%	6.82%	6.34%	5.46%	5.11%	3.86%	3.33%	2.99%	3.11%	3.21%
Mutual funds	13.05%	12.84%	10.60%	6.76%	6.26%	5.34%	5.07%	3.82%	3.25%	2.87%	2.79%	2.87%
Alternative investment funds	0.01%		0.04%	0.07%	0.08%	0.12%	0.04%	0.05%	0.07%	0.12%	0.32%	0.34%
	10.71%	11.49%	13.98%	17.82%	18.28%	19.22%	19.60%	20.73%	20.48%	21.17%	20.94%	20.39%
Retail (up to ₹2 lakh)	8.18%	8.99%	10.93%	14.45%	14.82%	14.88%	14.97%	14.58%	13.82%	14.36%	14.26%	14.07%
HNIs (above ₹2 lakh)	1.21%	1.50%	1.50%	1.50%	1.50%	2.04%	2.50%	3.71%	4.09%	3.95%	3.23%	3.02%
NRIs	0.31%	0.32%	0.40%	0.57%	0.59%	0.77%	0.78%	0.84%	0.85%	0.86%	0.92%	0.93%
Bodies corporate	0.46%	0.29%	0.66%	0.63%	0.69%	0.84%	0.69%	0.81%	0.83%	1.10%	1.47%	1.56%
No. of Shareholders	74,519	73,730	73,912	79,623	79,009	78,393	76,792	73,331	68,657	66,842	64,921	62,888

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Tatva Chintan Pharma Chem

Holder (above 1%)	Stake
Nippon India ELSS Tax Saver FundMutual fund	2.21%

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 2.87% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 11 Sep 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Tatva Chintan Pharma Chem Limited

What is the share price of Tatva Chintan Pharma Chem Limited today?

Tatva Chintan Pharma Chem Limited (TATVA) last traded at ₹1,944.00 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Tatva Chintan Pharma Chem Limited?

About ₹4,547 crore at the latest price.

What is the P/E ratio of Tatva Chintan Pharma Chem Limited?

About 88.5 times its earnings over the last 12 months.

Is Tatva Chintan Pharma Chem Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Tatva Chintan Pharma Chem Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Tatva Chintan Pharma Chem Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Tatva Chintan Pharma Chem Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Tatva Chintan Pharma Chem

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Tatva Chintan Pharma Chem Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next